Advertisement

Topics

Companies Related to "Osteoporosis and Chronic Obstructive Pulmonary Disease (COPD)" [Most Relevant Company Matches] RSS

22:05 EDT 20th August 2018 | BioPortfolio

Here are the most relevant search results for "Osteoporosis and Chronic Obstructive Pulmonary Disease (COPD)" found in our extensive corporate database of over 50,000 company records.

Showing "Osteoporosis Chronic Obstructive Pulmonary Disease COPD" Companies 1–25 of 3,100+

Extremely Relevant

COPD Foundation

Chronic Obstructive Pulmonary Disease (COPD) is the fourth leading cause of death in the U.S. and the only chronic disease growing in mortality. It affects approximately 24 million Americans but only 12 million are diagnosed. COPD includes chronic bronchitis, emphysema, and adult onset (refractory) asthma. Symptoms include breathlessness, wheezing, and chr...


The COPD Foundation

The mission of the COPD Foundation is to develop and support programs, which improve the quality of life through research, education, early diagnosis and enhanced therapy for persons whose lives are impacted by Chronic Obstructive Pulmonary Disease.

Spiros Development Corporation

Spiros Development Corporation develops the Spiros-Registered Trademark-, a dry powder pulmonary drug delivery system, and to conduct formulation work, clinical trials and commercialization for certain specified leading asthma and chronic obstructive pulmonary disease ("COPD") drugs for use with Spiros.


Uptake Medical Corp.

Uptake Medical(TM) Corp. is a developer of medical technologies for the treatment of lung diseases including emphysema. The core technology is a simple, minimally invasive, non-implant interventional pulmonary approach designed to measurably improve lung function and patient quality of life. Emphysema afflicts over 3 million people in the United States. It is a form of chronic obstructive pulmonar...

Synspira

Synspira is developing a new class of inhalable glycopolymer-based therapeutics that disrupt mucus accumulation and biofilm invasion, which are key drivers of pulmonary diseases including cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), and pneumonia. Synspira has an exclusive license from Synedgen to the Glycomics Technology Platform fo...

Pharmaxis Ltd

Pharmaxis (ACN 082 811 630) is a specialist pharmaceutical company involved in the research, development and commercialization of therapeutic products for chronic respiratory disorders. Its product Aridol® for the assessment of asthma is launched in a number of key markets. Its development pipeline of products includes: Bronchitol for cystic fibrosis, b...

Freedom Health, Inc. and Optimum Healthcare, Inc.

Headquartered in Tampa, FL, Freedom Health, Inc. and Optimum Healthcare Inc. provide comprehensive health care coverage through their Medicare Advantage Plans in the state of Florida. The health plans offer multiple benefit options including MAPD, Dual Special Needs Plans covering individuals with both Medicare and Medicaid eligibility and Chronic Special ...

MicroDose Therapeutx, Inc.

MicroDose Therapeutx is a privately-held pharmaceutical company dedicated to improving the quality of life for people suffering from serious diseases. The company focuses on developing proprietary products that address large unmet market opportunities, and on drug delivery platforms for the pulmonary, oral, and transdermal delivery of medications. The comp...

Hunter Immunology Limited

Our lead product is a vaccine currently called HI-164OV. It works by controlling bacterial colonisation of airways damaged by inhaled toxins. It has been developed to treat patients with Chronic Obstructive Pulmonary Disease (COPD) which includes bronchitis and emphysema. HI-164OV could help improve the lives of over one million Australians with COPD, and contribute towards saving Australia ...

Rotech Healthcare Inc.

Rotech Healthcare Inc. is one of the largest providers of home medical equipment and related products and services in the United States, with a comprehensive offering of respiratory therapy and durable home medical equipment and related services. The Company provides home medical equipment and related products and services principally to older patients wit...

EPIGENSISPHARMACEUTICALS

EPIGENSISPHARMACEUTICALSDevelop inhaled respiratory medicines that are safe, effective and improve the health and quality of life in patients with asthma, obstructive pulmonary disease (COPD), and other respiratory diseases. Develop inhaled respiratory medicines with commercially attractive target product profiles that address the unmet medical needs of patients with asthma and COPD, two of the l...

Almirall Ltd

Almirall, an international pharmaceutical company is based on innovation and committed to health. Headquartered in Barcelona, Spain, the company researches, develops, manufactures and commercialises its own R&D and licensed drugs with the aim of improving people's health and wellbeing. The therapeutic areas on which Almirall focuses its research resources are related to the treatment of asthma...

ResMed Inc.

ResMed (NYSE: RMD) (ASX: RMD), a world-leading connected health company with more than 5 million cloud-connected devices for daily remote patient monitoring, changes lives with every breath. Its award-winning devices and software solutions help treat and manage sleep apnea, chronic obstructive pulmonary disease and other respiratory conditions. Its 6,000-m...

Inverseon, Inc.

Inverseon's product development programs target significant unmet medical needs and major market opportunities in chronic pulmonary diseases such as asthma, COPD and pulmonary hypertension. Inverseon was founded based on the original work of Prof. Richard Bond of the University of Houston. Professor Bond termed the effects “Paradoxical Pharmacologyâ...

Entest BioMedical Inc.

Entest BioMedical Inc. (OTC Bulletin Board: ENTB) is a majority owned subsidiary of Bio-Matrix Scientific Group Inc (OTC Bulletin Board: BMSN). The Company is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), immuno-cancer therapies, testing procedures for diabetes, stem cell research applications for diabetes and other illnesses. The C...

Pearl Therapeutics Inc.

Pearl Therapeutics is developing combination therapies for the treatment of highly prevalent respiratory diseases, including chronic obstructive pulmonary disease (COPD) and asthma. Leveraging its proprietary particle technology, formulation expertise and unparalleled product development experience, Pearl is rapidly advancing a pipeline of products that offer patients and healthcare professionals ...

Ario Pharma Ltd

ario pharma ltd focusses on the development of drugs for the treatment of respiratory indications. Ario is about to evaluate the anti-tussive properties of XEN-D0501, a potential best-in-class TRPV1 inhibitor, in two Phase 2 clinical trials that will read out in 2014. The company is managed by a highly experienced development team and supported by world-renowned KOLs in respiratory disease. Co...

Bioxyne

Bioxyne Limited (ASX:BXN) is an Australian immunotherapeutics business created in April 2012 through the reverse takeover of Probiomics (ASX: PCC) by privately held Hunter Immunology. The Company’s lead therapy, HI-164OV is based on the Company’s proprietary technology that uses the application of mucosal immunology to treat common human diseases.  HI-164OV, in Phase IIb clinica...

Health Outcomes Worldwide

Health Outcomes Worldwide (HOW) is the leading provider of healthcare software solutions that empower healthcare organizations to improve patient care and significantly reduce costs. With its advanced data analytics and clinical evidence, the company’s award-winning how2trak® software helps nurses and physicians gain valuable knowledge to improve p...

Pharmacopeia Drug Discovery

Pharmacopeia is committed to discovering and developing novel therapeutics to address significant medical needs. The Company has a broad portfolio advancing toward clinical validation, both independently and with partners. Pharmacopeia's most advanced internal program is a dual-acting angiotensin and endothelin receptor antagonist (DARA) for hypertension and diabetic kidney disease for which Phase...

Theron Pharmaceuticals, Inc.

Headquartered in Sunnyvale, California, Theron Pharmaceuticals is committed to developing improved treatments for COPD and asthma. COPD is a slowly developing progressive small airways disease comprised broadly of chronic bronchitis and emphysema, and characterized by airflow limitation and decreased lung function. COPD is a major and growing health concer...

Biolipox AB (publ.)

Biolipox is a research-intensive pharmaceutical companyThe core of Biolipox's operations is world-leading research on arachidonic acid and its effects on inflammatory diseases - particularly asthma, chronic obstructive pulmonary disease (COPD), rhinitis, pain and arthritis. The discoveries that form the basis of our understanding of the role of arachidonic acid in inflammatory processes were rewar...

Relevant

MicroDose Technologies, Inc.

MicroDose Technologies, Inc. is a privately held premier drug delivery and specialty pharmaceuticals company. Founded in 1998, MicroDose is pioneering the use of proprietary drug delivery platforms for the pulmonary, oral and transdermal delivery of medications for improved efficacy and compliance. MicroDose's current focus is on the chronic disease states such as asthma, COPD, diabetes, hypertens...

Topigen Pharmaceuticals Inc.

TOPIGEN is developing several new classes of drugs and is actively progressing two drug candidates in Phase II trials for COPD and asthma. These drugs are uniquely focused on inhibiting multiple inflammation targets underlying the chronic pulmonary diseases. TOPIGEN also has a number of discovery research programs focused on the identification of novel compounds for the treatment of COPD and aller...

EPIX Pharmaceuticals

EPIX Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products through the use of proprietary technology to better diagnose, treat and manage patients. The company has five internally-discovered therapeutic and imaging drug candidates currently in clinical trials targeting conditions such as depression, Alzheimer's disease, ...


More From BioPortfolio on "Osteoporosis and Chronic Obstructive Pulmonary Disease (COPD)"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks